The success of sorafenib has spurred an explosive increase of clinical trials testing novel molecular targets and other agents in the treatment of hepatocellular carcinoma (HCC). The paradigm of the studies has been characterized by three noticeable changes. First, the molecular targets of interest have expanded from angiogenesis to cancer cell-directed oncogenic signaling pathways for advanced HCC treatment. Agents targeting EGFR, FGFR, PI3K/Akt/mTOR, TGF-β, c-Met, MEK, IGF signaling, and histone deacetylase have been actively explored. Second, the target indication has shifted from advanced stage to early or intermediate stages of disease. The feasibility of combining locoregional therapies and targeted agents, and the use of novel agents after curative treatments are currently under active investigation. Finally, the therapeutic strategy has shifted from monotherapy to combination targeted therapy. We aim to provide a comprehensive overview of newly disclosed and ongoing clinical trials for the treatment of HCC.
Sorafenib, a multi-target anti-angiogenic agent, was the first systemic therapy approved for the treatment of advanced hepatocellular carcinoma (HCC) [1, 2] . The success of sorafenib has spurred an explosive increase of clinical trials testing many novel molecular targeted agents in HCC. In recent years, the paradigm of the studies has been characterized by some noticeable changes. First, the molecular targets of interest have expanded from angiogenesis to cancer cell-directed oncogenic signaling pathways. Second, the target indication has shifted from advanced HCC toward early or intermediate HCC. Third, the therapeutic strategy has moved from monotherapy to combination therapy. In this article, we will provide a comprehensive, up-to-date review of clinical trials in HCC.
We searched for all interventional studies in HCC in ClinicalTrials.gov. Studies that met the following criteria were selected: (1) molecular targeted therapy as palliative treatment for advanced or intermediate HCC (in combination with locoregional therapies) or adjuvant treatment for early HCC following curative treatment; (2) studies which were open for recruitment (recruiting or not yet recruiting) as of February 2013 or studies which were closed (active but not recruiting, completed, suspended or terminated) after 2011. We also searched PubMed and meeting abstracts of the American Society of Clinical Oncology (ASCO), the American Association for the Study of Liver Diseases (AASLD), the International Liver Congress, the International Liver Cancer Association (ILCA), and the Asian Pacific Association for the Study of Liver (APASL) from January 2011 to February 2013 for full or interim reports of those included trials. The following data from published studies are shown in the tables: number of evaluable patients, objective response rate (ORR), disease control rate (DCR), time-to-progression (TTP), progression-free survival (PFS) and overall survival (OS).
Clinical Trials of Molecular Targeted Therapy for Advanced HCC
Data from clinical trials on a variety of molecular targeted therapies for advanced HCC are shown in table 1 .
Anti-angiogenic Agents
Angiogenesis is so far the most extensively studied therapeutic target of HCC. The efficacy of novel anti-angiogenic tyrosine kinase inhibitors (TKI) for sorafenib-naive advanced HCC has been investigated in several phase III, randomized, controlled trials. However, to date, none of these novel anti-angiogenic TKIs has exhibited superior efficacy to sorafenib. Sunitinib [3] and linifanib (ABT-869) [9] , both primarily targeting vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), failed to prolong OS compared to sorafenib (8.1 months for sunitinib vs. 10.0 months for sorafenib, P = 0.0019; 9.1 months for linifanib vs. 9.8 months for sorafenib, P > 0.05), and were associated with relatively more grade 3 or 4 adverse events than sorafenib was. Brivanib, which targets VEGFR, PDGFR and fibroblast growth factor receptor (FGFR), also failed to prolong OS (9.5 months for brivanib vs. 9.9 months for sorafenib, P > 0.05) but had a more favorable toxicity profile than sorafenib [5] . Lenvatinib (E7080), a TKI of VEGFR, PDGFR, FGFR, RET and c-Kit, resulted in a high ORR of 33% per modified response evaluation criteria in solid tumors (mRECIST) in a phase I/II trial [12] , and is currently undergoing phase III investigation.
The efficacy of brivanib after sorafenib failure has also been investigated in a phase III, randomized, placebo-controlled study (BRISK-PS study) [6] . Brivanib, compared to placebo, resulted in a higher ORR (11.5% vs. 1.9%; per mRECIST) and a longer median TTP (4.3 months vs. 2.7 months, P = 0.0001), but did not significantly increase the OS (9.4 months 9.1 (NS) [9] Sorafenib 400 mg po bid • The tumor response was defined per modified WHO criteria. e The tumor response was defined per modified RECIST. * The evaluation criteria was not mentioned.
vs. 8.2 months, P = 0.33). The efficacy of other second-line anti-angiogenic agents (ramucirumab, regorafenib and axitinib) remains undetermined.
EGFR Inhibitor
The combination of anti-angiogenic therapy and erlotinib has been investigated. In a phase III, randomized, controlled, double-blind trial (SEARCH trial) [22] , sorafenib plus erlotinib, compared to sorafenib plus placebo, did not prolong either TTP (3.2months vs. 4.0 months, P > 0.05) or OS (9.5 months vs. 8.5 months; P > 0.05). In several completed phase II single-arm studies, bevacizumab (anti-VEGF monoclonal antibody) plus erlotinib resulted in a modest anti-tumor activity compared to the historical control of sorafenib or bevacizumab [23] [24] [25] .
mTOR Inhibitors Everolimus (RAD001) is the most extensively studied mTOR inhibitor for the treatment of HCC. The recommended phase II dose of everolimus was 7.5 or 10 mg per day for monotherapy in HCC patients [28, 29] . A phase III, randomized, placebo-controlled trial testing the efficacy of everolimus 7.5 mg po qd after sorafenib failure has completed patient recruitment, and the results will be available by the end of 2013. The maximum tolerated dose of everolimus was determined to be 2.5 mg per day for combination with sorafenib [26] . However, everolimus at this dose level was considered biologically inactive and unlikely to improve the efficacy of sorafenib through mTOR inhibition.
A phase II trial testing the efficacy of temsirolimus 25 mg iv weekly plus bevacizumab 10 mg/kg iv biweekly for first-line treatment was prematurely stopped due to futility [31] . However, the same combination regimen resulted in a higher ORR (per conventional RE-CIST) of 30.7% and fair tolerability in the first 13 patients in a phase II trial for patients in whom sorafenib failed [32] .
c-Met Inhibitors c-Met signaling is considered essential for hepatocarcinogenesis [57] . Foretinib (GSK 136089), the first multi-target c-MET TKI to undergo clinical investigation, produced a promising ORR (per mRECIST) of 24%, median TTP of 4.2 months, and median OS of 15.7 months in 38 sorafenib-naïve HCC patients [39] . Other c-Met inhibitors have been primarily evaluated in HCC patients in whom sorafenib had failed. Tivantinib (ARQ 197), a selective non-ATP competitive inhibitor of c-MET, has been tested in a phase II, randomized, placebocontrolled trial [35] . Tivantinib, compared to placebo, improved median TTP from 1.4 to 1.6 months in molecularly unselected HCC patients with a hazard ratio (HR) of 0.64 (P = 0.04). Importantly, tivantinib almost doubled median TTP (2.7 months vs. 1.4 months, HR = 0.43, P = 0.03) and median OS (7.2 months vs. 3.8 months, HR = 0.38, P = 0.01) in patients with high c-Met-expressing tumors (≥2+ staining intensity in ≥50% of tumor cells by an immunohistochemical method). A confirmatory phase III, randomized, placebo-controlled trial was subsequently launched to evaluate the efficacy of tivantinib in HCC patients who had high cMet expression in their tumors and developed progressive disease under sorafenib therapy. c-Met inhibitors are generally well tolerated except for increased incidence of grade 3 or 4 neutropenia, anemia and thrombocytopenia (14.1, 11.3 and 5.6%, respectively).
MEK Inhibitors
Selumetinib (AZD6244) 100 mg po bid resulted in a short TTP of 1.8 months in the first 19 treatment-naïve HCC patients of a phase II trial, although it did induce down-regulation of ERK phosphorylation in post-treatment tumor tissue [40] . Selumetinib [41] and BAY86-9766 [42] were investigated in early-phase trials for their combination activity with sorafenib. The combination of sorafenib and selumetinib resulted in an ORR of 27.3% in the first 11 patients, but this finding needs to be validated.
Inhibitors of IGF Signaling
Several IGF-or IGF-1R-targeted agents, either as single agents or in combination with sorafenib, have undergone early-phase investigations [43, 44] . However, several toxicities, such as hyperglycemia, hyperbilirubinemia and elevation of liver enzymes, following combination therapy have limited the development of OSI-906, AVE1642 and BIIB022.
Other Molecular Targeted Agents
Many other signaling pathways are also involved in hepatocarcinogenesis, including histone deacetylase (HDAC), tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1), death receptor 5 (DR5), X-linked inhibitor of apoptosis protein (XIAP), proteasome, retinoid receptor, peroxisome proliferator-activated receptor α (PPARα), phospholipid, transformation growth factor-β (TGF-β), AKT, STAT3 and cyclin-dependent kinases. In addition, some molecular targets expressed either on immune cells (such as cytotoxic T-lymphocyte antigen and programmed death-1) or cancer cells (such as A3 adenosine receptor and glypican 3) provide opportunities for immunotherapy. Corresponding targeted agents are being actively studied in phase I/II or II trials for their feasibility. Noticeably, lenalidomide (an immune moderator) resulted in a higher ORR of 22% per conventional RECIST (two complete responders and six partial responders) in 37 American patients in whom sorafenib had failed [54] . Another study testing the efficacy of lenalidomide as second-line treatment is ongoing in Asian HCC patients.
Clinical Trials of Molecular Targeted Therapy in Combination with Locoregional Therapy
Data from clinical trials on a variety of molecular targeted therapies in combination with locoregional therapy are shown in table 2 [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] .
Sorafenib
The feasibility of combining locoregional therapy and sorafenib for HCC treatment has been evaluated in many clinical trials. In a phase III, randomized, placebo-controlled trial, patients whose hepatic tumors had ≥25% tumor necrosis/shrinkage after one or two sessions of transarterial chemoembolization (TACE) were randomized to sorafenib or placebo. However, the addition of sorafenib failed to prolong TTP (5.4 months vs. 3.7 months; HR = 0.87; P = 0.252) [58] . Subsequently, a number of phase II trials evaluating the efficacy and safety of conventional TACE or TACE with doxorubicin-eluting beads (DEB) with concurrent sorafenib (which started within 14 days before or after TACE was carried out) revealed inconsistent results [59] [60] [61] [62] [63] [64] . The diversity of study designs created confounding factors including primary endpoints, patient populations, TACE procedures, timing of randomization, and drug administration may account for these conflicting results [69] . Another two phase III, randomized, placebo-controlled trials evaluating the efficacy of sorafenib in combination with conventional TACE or DEB-TACE are ongoing.
In the phase II SORAMIC trial (local ablation group), patients with early HCC receive a maximum of two curative radiofrequency ablation (RFA) sessions. Randomization to sorafenib or placebo was performed after completion of RFA. Several phase I or II trials eval- uating the efficacy and/or safety of radiotherapy in combination with sorafenib in patients with early HCC are actively recruiting patients.
Other Anti-angiogenic Agents and Everolimus
Several phase II trials explored the efficacy of combining TACE and anti-angiogenic agents, such as sunitinib [65] , bevacizumab [66, 67] and orantinib (TSU-68) [68] . Most of these trials demonstrated promisingly long TTP. Further phase III, randomized, controlled trials exploring the combinations of TACE and sunitinib (TURNE trial), orantinib (ORIENTAL trial) and brivanib (BRISK-TA trial) are ongoing. In addition, the efficacy of DEB-TACE with everolimus is currently being explored in two phase II, randomized, controlled trials.
Clinical Trials of Adjuvant Molecular Targeted Therapy Following Curative Treatment
The potential of molecular targeted agents as adjuvant therapy after curative surgery, local ablation or liver transplantation is under active investigation; most studies are still ongoing. In a phase II trial with a limited number of patients (30 patients in total), sorafenib following curative surgery resulted in a lower tumor recurrence rate (33.3% vs. 73.6%), compared to surgery alone [70] . A large-scale, phase III, randomized, placebo-controlled trial (STORM trial) evaluating the efficacy of sorafenib after curative surgery or local ablation has completed accrual.
PI-88, a heparanase inhibitor, has been testing as adjuvant therapy for HCC after curative resection. A phase II study suggested that PI-88 at 160 mg/day is potentially effective as adjuvant therapy in postoperative HCC patients [71] . A phase III, randomized, placebo-controlled trial exploring the value of PI-88 in the adjuvant setting is ongoing. Data from clinical trials of adjuvant molecular targeted therapy following curative treatment are shown in table 3 [70, 71] . OLT = orthotopic liver transplant; sc = subcutaneous injection. * Time-to-recurrence at the 36th percentile.
